AlphaVax Inc. agreed to license rights to its Phase I-stage cytomegalovirus (CMV) vaccine program to Novartis AG in exchange for a $20 million up-front payment, plus the possibility of an equity investment, milestones and royalties down the road. (BioWorld Today) Read More
